BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
169 hedge funds and large institutions have $2.74B invested in bluebird bio in 2014 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 53 increasing their positions, 42 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
37% more funds holding
Funds holding: 123 → 169 (+46)
26% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 42
Holders
169
Holding in Top 10
7
Calls
$43.4M
Puts
$14.5M
Top Buyers
| 1 | +$75M | |
| 2 | +$69M | |
| 3 | +$43.8M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$40M |
Top Sellers
| 1 | -$50.5M | |
| 2 | -$37.4M | |
| 3 | -$20.4M | |
| 4 |
QF
QVT Financial
New York
|
-$18.7M |
| 5 |
State Street
Boston,
Massachusetts
|
-$18.2M |